tirzepatide mash fda The has granted accelerated approval for Wegovy (semaglutide 2.4 mg, once‑weekly) to treat metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2–F3) without cirrhosis. This is standout Resmetirom and Thyroid Hormone Receptor‐Targeted

GLP-1 stimulates insulin secretion in response to elevated blood glucose, suppresses glucagon release, slows gastric emptying, and reduces appetite

Over the past decade, several studies have indicated that metformin can lower thyroid-stimulating hormone (TSH) levels in individuals with diabetes

When you give blood, everything removed from your body is kept and utilized by the organization you donated to

Whilst most injection site reactions are benign and self-resolving, certain features warrant prompt medical assessment to exclude complications such as infection, abscess formation, or hypersensitivity reactions

For instance, in the STEP 2 trial, nausea from semaglutide rose from 5% at week 1 to 15% by week 13, then decreased to 8% by week 68